Pinto X - Search Results

1

[Apolipoprotein E polymorphism and coronary disease].

Peña R, M Mostaza J, Lahoz C, Jiménez J, Subirats E, Pinto X, Taboada M, López-Pastor A, del Estudio RAP g. Peña R, et al. Among authors: pinto x. Med Clin (Barc). 2001 May 19;116(18):681-5. doi: 10.1016/s0025-7753(01)71952-5. Med Clin (Barc). 2001. PMID: 11412677 Spanish.

2

[Early detection of dyslipidemias. Is the isolated determination of total cholesterol efficient?].

Argimón JM, Fiol C, Pintó X, Bros R, Jiménez J, Hurtado I, Castiñeiras MJ. Argimón JM, et al. Among authors: pinto x. Med Clin (Barc). 1991 Nov 30;97(19):729-32. Med Clin (Barc). 1991. PMID: 1800861 Spanish.

3

[Effectiveness of hypercholesterolemia detection in high risk individuals compared to opportunistic detection].

Argimón JM, Fiol C, Pintó X, Hurtado I, Gracia V. Argimón JM, et al. Among authors: pinto x. Med Clin (Barc). 1994 Jan 29;102(3):86-9. Med Clin (Barc). 1994. PMID: 8133718 Spanish.

4

[Risk factors of arteriopathy of the lower extremities: lipid and not lipid factors].

Pintó X, Fiol C, Simeón JM, Capdevila JM, Barjau E, Argimón JM, Moga I, Pujol R. Pintó X, et al. Med Clin (Barc). 1997 Jun 7;109(2):41-4. Med Clin (Barc). 1997. PMID: 9280799 Spanish.

5

[Efficacy of hygienic and dietary therapy in coronary patients with isolated hypoalphalipoproteinemia].

Meco JF, Pinto X, Quintana E, Fiol C, Castiñeiras MJ, Pujol R. Meco JF, et al. Among authors: pinto x. An Med Interna. 1999 Dec;16(12):620-5. An Med Interna. 1999. PMID: 10686713 Clinical Trial. Spanish.

6

Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting.

Peña R, Lahoz C, Mostaza JM, Jiménez J, Subirats E, Pintó X, Taboada M, López-Pastor A; Rap Study Group. Peña R, et al. Among authors: pinto x. J Intern Med. 2002 Jun;251(6):518-25. doi: 10.1046/j.1365-2796.2002.00991.x. J Intern Med. 2002. PMID: 12028507 Free article.

7

Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy.

Lahoz C, Peña R, Mostaza JM, Jiménez J, Subirats E, Pintó X, Taboada M, López-Pastor A; RAP Study Group. Lahoz C, et al. Among authors: pinto x. Atherosclerosis. 2003 Jun;168(2):289-95. doi: 10.1016/s0021-9150(03)00094-7. Atherosclerosis. 2003. PMID: 12801612

8

Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.

Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X. Lahoz C, et al. Among authors: pinto x. Metabolism. 2005 Jun;54(6):741-7. doi: 10.1016/j.metabol.2004.12.020. Metabolism. 2005. PMID: 15931608 Clinical Trial.

9

The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment.

Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X; RAP Study Group. Lahoz C, et al. Among authors: pinto x. Atherosclerosis. 2005 Sep;182(1):129-34. doi: 10.1016/j.atherosclerosis.2005.02.001. Epub 2005 Feb 26. Atherosclerosis. 2005. PMID: 16115483 Clinical Trial.

10

[Factors influencing incipient diabetic nephropathy: ESODIAH study].

Biarnés J, Masana L, Morales C, Pintó X, Ricart W; Grupo del estudio ESODIAH. Biarnés J, et al. Among authors: pinto x. Med Clin (Barc). 2005 Oct 1;125(11):401-4. doi: 10.1157/13079380. Med Clin (Barc). 2005. PMID: 16216183 Spanish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

439 results

Search Page

Filters